{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:35:56Z","timestamp":1787067356913,"version":"build-2736575974"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2019,3,18]],"date-time":"2019-03-18T00:00:00Z","timestamp":1552867200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006808","name":"University of North Carolina","doi-asserted-by":"publisher","award":["R25TW009340"],"award-info":[{"award-number":["R25TW009340"]}],"id":[{"id":"10.13039\/100006808","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008799","name":"Gilead Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008799","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1115209"],"award-info":[{"award-number":["OPP1115209"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["R21AI135756"],"award-info":[{"award-number":["R21AI135756"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1115887"],"award-info":[{"award-number":["OPP1115887"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,10,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Tuberculosis is the primary infectious disease killer worldwide, with a growing threat from multidrug-resistant cases. Unfortunately, classic growth-based phenotypic drug susceptibility testing (DST) remains difficult, costly, and time consuming, while current rapid molecular testing options are limited by the diversity of antimicrobial-resistant genotypes that can be detected at once. Next-generation sequencing (NGS) offers the opportunity for rapid, comprehensive DST without the time or cost burden of phenotypic tests and can provide useful information for global surveillance. As access to NGS expands, it will be important to ensure that results are communicated clearly, consistent, comparable between laboratories, and associated with clear guidance on clinical interpretation of results. In this viewpoint article, we summarize 2 expert workshops regarding a standardized report format, focusing on relevant variables, terminology, and required minimal elements for clinical and laboratory reports with a proposed standardized template for clinical reporting NGS results for Mycobacterium tuberculosis.<\/jats:p>","DOI":"10.1093\/cid\/ciz219","type":"journal-article","created":{"date-parts":[[2019,3,14]],"date-time":"2019-03-14T04:59:33Z","timestamp":1552539573000},"page":"1631-1633","source":"Crossref","is-referenced-by-count":16,"title":["Building the Framework for Standardized Clinical Laboratory Reporting of Next-generation Sequencing Data for Resistance-associated Mutations in Mycobacterium tuberculosis Complex"],"prefix":"10.1093","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1566-4622","authenticated-orcid":false,"given":"Jeffrey A","family":"Tornheim","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela M","family":"Starks","sequence":"additional","affiliation":[{"name":"Division of Tuberculosis Elimination, National Center for HIV\/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy C","family":"Rodwell","sequence":"additional","affiliation":[{"name":"Foundation for Innovative New Diagnostics, Geneva, Switzerland"},{"name":"Division of Pulmonary, Critical Care, and Sleep Medicine, University of San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L","family":"Gardy","sequence":"additional","affiliation":[{"name":"School of Population and Public Health, University of British Columbia, Canada"},{"name":"Clinical Prevention Services, British Columbia Centre for Disease Control, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy M","family":"Walker","sequence":"additional","affiliation":[{"name":"Nuffield Department of Medicine, University of Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela M","family":"Cirillo","sequence":"additional","affiliation":[{"name":"IRCCS San Raffaele Scientific Institute, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi","family":"Jayashankar","sequence":"additional","affiliation":[{"name":"Columbus Technologies, Inc. Contractor to the National Institute of Allergy and Infectious Diseases, US National Institutes of Health, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Miotto","sequence":"additional","affiliation":[{"name":"IRCCS San Raffaele Scientific Institute, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Zignol","sequence":"additional","affiliation":[{"name":"Global TB Programme, World Health Organization, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Schito","sequence":"additional","affiliation":[{"name":"Critical Path to Tuberculosis Drug Regimens, Critical Path Institute, Tucson, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,3,18]]},"reference":[{"key":"2019123108580613600_CIT0001","volume-title":"Global Tuberculosis Report 2018","author":"World Health Organization","year":"2018"},{"key":"2019123108580613600_CIT0002","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1473-3099(17)30247-5","article-title":"Estimating the future burden of multidrug-resistant and extensively drug-resistant tuberculosis in India, the Philippines, Russia, and South Africa: a mathematical modelling study","volume":"17","author":"Sharma","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2019123108580613600_CIT0003","volume-title":"WHO endorses new rapid tuberculosis test [press release]","year":"2010"},{"key":"2019123108580613600_CIT0004","volume-title":"Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB): policy statement June 27, 2008","author":"World Health Organization","year":"2008"},{"key":"2019123108580613600_CIT0005","volume-title":"The use of molecular line probe assays for the detection of resistance to second-line anti-tuberculosis drugs: policy guidance","author":"World Health Organization","year":"2016"},{"key":"2019123108580613600_CIT0006","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1056\/NEJMsr1512438","article-title":"Twenty years of global surveillance of antituberculosis-drug resistance","volume":"375","author":"Zignol","year":"2016","journal-title":"N Engl J Med"},{"key":"2019123108580613600_CIT0007","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1016\/j.ijmyco.2016.09.010","article-title":"Best approaches to drug-resistance surveillance at the country level","volume":"5","author":"Cabibbe","year":"2016","journal-title":"Int J Mycobacteriol"},{"key":"2019123108580613600_CIT0008","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S1473-3099(18)30073-2","article-title":"Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study","volume":"18","author":"Zignol","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2019123108580613600_CIT0009","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S1473-3099(17)30123-8","article-title":"Tuberculosis is changing","volume":"17","author":"Walker","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2019123108580613600_CIT0010","volume-title":"CDC invests more than $200 million to help states respond to infectious disease threats [press release]","year":"2017"},{"key":"2019123108580613600_CIT0011","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1128\/JCM.00298-17","article-title":"Comprehensive whole-genome sequencing and reporting of drug resistance profiles on clinical cases of Mycobacterium tuberculosis in New York State","volume":"55","author":"Shea","year":"2017","journal-title":"J Clin Microbiol"},{"key":"2019123108580613600_CIT0012","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/S1473-3099(16)30190-6","article-title":"Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project","volume":"16","author":"Zignol","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2019123108580613600_CIT0013","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S1473-3099(18)30132-4","article-title":"EUSeqMyTB to set standards and build capacity for whole genome sequencing for tuberculosis in the EU","volume":"18","author":"Tagliani","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2019123108580613600_CIT0014","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12916-016-0598-2","article-title":"Clinical use of whole genome sequencing for Mycobacterium tuberculosis","volume":"14","author":"Witney","year":"2016","journal-title":"BMC Med"},{"key":"2019123108580613600_CIT0015","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.cmi.2017.10.030","article-title":"Mycobacterium tuberculosis and whole-genome sequencing: how close are we to unleashing its full potential?","volume":"24","author":"Satta","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"2019123108580613600_CIT0016","doi-asserted-by":"crossref","first-page":"e1002824","DOI":"10.1371\/journal.ppat.1002824","article-title":"Routine use of microbial whole genome sequencing in diagnostic and public health microbiology","volume":"8","author":"Koser","year":"2012","journal-title":"PLoS Pathog"},{"key":"2019123108580613600_CIT0017","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1128\/JCM.02483-16","article-title":"Same-day diagnostic and surveillance data for tuberculosis via whole-genome sequencing of direct respiratory samples","volume":"55","author":"Votintseva","year":"2017","journal-title":"J Clin Microbiol"},{"key":"2019123108580613600_CIT0018","volume-title":"The need to harmonize clinical laboratory test results","author":"American Association for Clinical Chemistry","year":"2015"},{"key":"2019123108580613600_CIT0019","doi-asserted-by":"crossref","first-page":"24","DOI":"10.5588\/ijtld.15.0221","article-title":"Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a TBNET\/RESIST-TB consensus statement","volume":"20","author":"Dominguez","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"key":"2019123108580613600_CIT0020","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01354-2017","article-title":"A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis","volume":"50","author":"Miotto","year":"2017","journal-title":"Eur Respir J"},{"key":"2019123108580613600_CIT0021","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1093\/cid\/civ610","article-title":"Collaborative effort for a centralized worldwide tuberculosis relational sequencing data platform","volume":"61","author":"Starks","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2019123108580613600_CIT0022","volume-title":"The use of next-generation sequencing technologies for the detection of mutations associated with drug resistance in Mycobacterium tuberculosis complex: technical guide","author":"World Health Organization","year":"2018"},{"key":"2019123108580613600_CIT0023","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1056\/NEJMoa1800474","article-title":"Prediction of susceptibility to first-line tuberculosis drugs by DNA sequencing","volume":"379","author":"The CRyPTIC Consortium","year":"2018","journal-title":"New England J Med"},{"key":"2019123108580613600_CIT0024","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.cmi.2016.10.022","article-title":"Mycobacterium tuberculosis drug-resistance testing: challenges, recent developments and perspectives","volume":"23","author":"Schon","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"2019123108580613600_CIT0025","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1128\/JCM.00025-15","article-title":"PhyResSE: a web tool delineating Mycobacterium tuberculosis antibiotic resistance and lineage from whole-genome sequencing data","volume":"53","author":"Feuerriegel","year":"2015","journal-title":"J Clin Microbiol"},{"key":"2019123108580613600_CIT0026","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cmi.2016.09.006","article-title":"Consensus numbering system for the rifampicin resistance-associated rpoB gene mutations in pathogenic mycobacteria","volume":"23","author":"Andre","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"2019123108580613600_CIT0027","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/humu.22981","article-title":"HGVS recommendations for the description of sequence variants: 2016 update","volume":"37","author":"den Dunnen","year":"2016","journal-title":"Hum Mutat"},{"key":"2019123108580613600_CIT0028","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"2019123108580613600_CIT0029","doi-asserted-by":"crossref","first-page":"80.e1","DOI":"10.1016\/j.medcli.2017.12.010","article-title":"Consensus document on the implementation of next generation sequencing in the genetic diagnosis of hereditary cancer","volume":"151","author":"Soto","year":"2018","journal-title":"Med Clin (Barc)"},{"key":"2019123108580613600_CIT0030","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/ejhg.2015.226","article-title":"Guidelines for diagnostic next-generation sequencing","volume":"24","author":"Matthijs","year":"2016","journal-title":"Eur J Hum Genet"},{"key":"2019123108580613600_CIT0031","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S1473-3099(15)00062-6","article-title":"Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study","volume":"15","author":"Walker","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"2019123108580613600_CIT0032","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00344-18","article-title":"Validating a 14-drug microtiter plate containing bedaquiline and delamanid for large-scale research susceptibility testing of Mycobacterium tuberculosis","volume":"62","author":"Rancoita","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2019123108580613600_CIT0033","doi-asserted-by":"crossref","first-page":"e4218","DOI":"10.7717\/peerj.4218","article-title":"Evidence-based design and evaluation of a whole genome sequencing clinical report for the reference microbiology laboratory","volume":"6","author":"Crisan","year":"2018","journal-title":"PeerJ"},{"key":"2019123108580613600_CIT0034","volume-title":"ReSeqTB: relational sequencing TB data platform"},{"key":"2019123108580613600_CIT0035","volume-title":"Technical report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis","author":"World Health Organization","year":"2018"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciz219\/28700221\/ciz219.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/69\/9\/1631\/31666064\/ciz219.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/69\/9\/1631\/31666064\/ciz219.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,31]],"date-time":"2019-12-31T08:58:46Z","timestamp":1577782726000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/69\/9\/1631\/5382557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,18]]},"references-count":35,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,3,18]]},"published-print":{"date-parts":[[2019,10,15]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciz219","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,11,1]]},"published":{"date-parts":[[2019,3,18]]}}}